Amazon earnings miss; NASDAQ 100 losing steam; IFO expectations showing turning point? Amazon earnings miss; NASDAQ 100 losing steam; IFO expectations showing turning point? Amazon earnings miss; NASDAQ 100 losing steam; IFO expectations showing turning point?

Amazon earnings miss; NASDAQ 100 losing steam; IFO expectations showing turning point?

Equities 5 minutes to read
PG
Peter Garnry

Head of Equity Strategy

Summary:  In today's equity update we obviously talk about Amazon's Q3 earnings result last night that missed on EPS and AWS revenue growth while the real kicker was the Q4 revenue range guidance not even hitting consensus estimate. The shares were down 7% in extended trading and will have an impact on the NASDAQ 100 Index in today's session. This means more pressure on Alphabet, Apple and Facebook to deliver strong earnings next week if equity markets in the US are to print new highs. We also talk about today's IFO survey beating expectations and raising the hope for a turning point in the European economy although many macro indicators are still mixed.


The biggest event in equities happened last night after the US market close when Amazon reported Q3 earnings which missed on bottom line but delivered a small beat on revenue. But even worse, Amazon put forth Q4 revenue guidance with the high range below consensus estimate which turned out to be the kicker sending the shares down 7% in extended trading closing at 1,660 (red line on chart). Adding salt to the wound AWS Q3 revenue missed estimates as well indicating faster growth decline than anticipated by analysts. This could lead to a change in valuation for Amazon. One of the things mentioned in the Q3 report was rising logistics costs as the company is pushing out one-day shipping for Prime customers. There are two things likely at play here. Walmart is intensifying the competition for Amazon’s e-commerce business and Microsoft is becoming a formidable competitor in the cloud business. It was the second straight quarter of EPS missing estimates which is the first time since 2014.

Source: Saxo Bank

Amazon is the third largest component in the NASDAQ 100 Index with a 9% weight so the index will most likely be weighed down by Amazon in today’s session. Even before Amazon’s earnings the index looked like it was losing steam. For NASDAQ 100 to print a new all-time high it requires strong earnings releases from Apple, Facebook and Alphabet, all reporting earnings next week, that combined represent a weight of 25% of the index.

Source: Saxo Bank

Yesterday’s France PMI figures for October indicated that economic activity is stabilizing in Europe and potentially Europe is getting closer to a turning point. The German IFO survey today shows better than expected expectations in October at 91.5 vs est. 91.0 and up from 90.9 in September. Maybe the green shoots are real. However, our view is that macro indicators are still too mixed to be calling for a turning point, so our expectation is still for the global economy to slow down further over the coming months. The potential catalyst for European equities is more momentum in European new car registrations, which just recently turned positive y/y again, and better numbers out of Asia. If the global leading indicators from OECD turn higher then the global economy is entering the recovery phase and as our table below shows, then European and Emerging Market equities are the most likely winners. Especially Swedish equities look interesting given their pro-cyclical nature and the Riskbank’s decision yesterday to take rates to zero which could add further tailwind to SEK in top of gains from a change in the business cycle. For foreign investors, Swedish equities could become one of the best equity markets next year.

Next week is the busiest in the entire earnings season with around 730 companies reporting earnings in the universe we track. The table below shows the 30 largest companies on market value reporting earnings. The key earnings to watch are Alphabet, Amgen, Merck, Pfizer, GlaxoSmithKline, Apple, Facebook, Sanofi, Bristol-Myers, Novo Nordisk and AbbVie. These are the bellwethers of the technology and health care sectors, the two largest sectors in global equity markets, and thus are very important for equity market direction and the potential for new highs.

Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.